Stock Events

Regenicin 

$0
5
+$0+0% Thursday 20:00

Statistics

Day High
0
Day Low
0
52W High
0.01
52W Low
0
Volume
15,000
Avg. Volume
2,270
Mkt Cap
16,577
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

12AugConfirmed
Q2 2020
Q4 2020
Q1 2021
Q2 2021
Q4 2021
Q1 2022
Q2 2022
-0
-0
-0
0
Expected EPS
N/A
Actual EPS
-0.0012

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RGIN. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap169.83B
Pfizer is involved in biopharmaceuticals, including regenerative medicine, making it a competitor in the broader biotech and healthcare sector.
Novartis
NVS
Mkt Cap232.42B
Novartis focuses on innovative medicines, including those in regenerative medicine, directly competing in the same industry as Regenicin.
Merck &
MRK
Mkt Cap318.55B
Merck operates in the pharmaceuticals sector, focusing on innovative treatments that could overlap with Regenicin's regenerative medicine technologies.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Johnson & Johnson, through its subsidiary companies, is involved in the research and development of new healthcare solutions, including regenerative medicine.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences is a biopharmaceutical company that develops medicines in areas of unmet medical need, including regenerative medicine.
AMGEN
AMGN
Mkt Cap177.72B
Amgen is a biotech company focusing on human therapeutics, with interests in regenerative medicine and tissue healing, competing with Regenicin's niche.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol Myers Squibb is engaged in the discovery, development, and delivery of medicines, including those in the regenerative medicine space.
Abbvie
ABBV
Mkt Cap304.29B
AbbVie operates in the pharmaceuticals sector, focusing on innovative treatments, including regenerative medicine, which puts it in competition with Regenicin.
Roche
RHHBY
Mkt Cap220.72B
Roche Holding AG focuses on pharmaceuticals and diagnostics, with a strong emphasis on innovation in medicine, including regenerative therapies.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca is a global, science-led biopharmaceutical business that works in several therapeutic areas, including regenerative medicine, competing with Regenicin's focus.

About

Miscellaneous Commercial Services
Manufacturing
Commercial Services
Industrial and Commercial Fan and Blower and Air Purification Equipment Manufacturing
Biotechnology
Health Technology
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. Its products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.
Show more...
CEO
Employees
3
Country
US
ISIN
US75887Q1022

Listings

OTCM
US
RGIN